|Bid||637.00 x 0|
|Ask||637.15 x 0|
|Day's range||635.45 - 642.60|
|52-week range||355.30 - 692.50|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||33.30|
|Earnings date||05-Aug-2020 - 10-Aug-2020|
|Forward dividend & yield||6.00 (0.95%)|
|1y target est||592.05|
India's Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at 5,400 rupees ($71) per 100-milligram vial, the drugmaker said on Wednesday, as it prepares to ship them to hospitals in the country. The privately held company said it would supply 20,000 vials of the drug. Fellow Indian drug firm Cipla Ltd had said on Tuesday that its own version of the antiviral drug remdesivir would be priced below 5,000 rupees.
Indian drugmaker Cipla Ltd will price its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in COVID-19 patients at less than 5,000 rupees ($66), the company said. Cipla and privately held Indian drugmaker Hetero Labs on Sunday gained approval to sell generic versions of remdesivir in the country. Hetero expects to price a similar 100 milligram dose of the treatment at 5,000 to 6,000 rupees.
The drug, which will be marketed under the brand name Covifor, will likely be priced at 5,000 to 6,000 rupees ($66-$79) for a 100 milligram dose, Hetero said. India's Cipla said its generic version of remdesivir will be called Cipremi. The Drug Controller General of India (DCGI) was not immediately available for comment.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Readers hoping to buy Cipla Limited (NSE:CIPLA) for its dividend will need to make their move shortly, as the stock is...